MBX Biosciences, Inc. Common Stock (MBX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 63
- Market Cap
- $3.2B
About MBX Biosciences, Inc. Common Stock
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
SentiSense also tracks daily options readings for MBX Biosciences, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
MBX Biosciences, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.